Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Merck KGaA Buys Into Threshold Cancer Drug
by Lisa M. Jarvis
February 13, 2012
| A version of this story appeared in
Volume 90, Issue 7
Merck KGaA will pay Threshold Pharmaceuticals $25 million up front and up to $525 million in milestones for access to the cancer treatment TH-302. Merck will also cover 70% of the development costs for TH-302, a small molecule that is activated in tumor cell environments where the oxygen concentration is low. A Phase III trial testing the compound in soft-tissue sarcoma is under way, and Threshold expects to reveal data from a Phase II trial in pancreatic cancer later this month. Threshold retains an option to jointly sell the drug in the U.S.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X